Projects

Top Sector Life Sciences & Health (LSH) entails a broad scope of disciplines, from pharmaceuticals to medical technology and from healthcare infrastructure to vaccination. To realise its mission – vital citizens in a healthy economy - the Top Sector builds on the strengths of the Dutch LSH sector to address the biggest societal challenges in prevention, cure and care. By funding multidisciplinary public-private partnerships (PPPs) the Top Sector aims to facilitate innovation. Here we give an overview of  a number of funded R&D projects by Top Sector LSH. The page is updated continuously.

Development of next-generation Vero cells to improve vaccine production

Deciphering cellular proteins and pathways involved in virus replication and in suspension growth of Vero cells

Despite the critical role for vaccines in public health, there are issues with costs and manufacturing that prevent a significant portion of the world’s population from accessing vaccines.

The aim of this project is to make the production of viral vaccines less expensive. To achieve this, Intravacc aims at the identification of cellular pathways that are important in virus replication and suspension growth in Vero cells. By permanent modification of the identified host factors, Vero cell lines can be constructed that are better suited for the production of viral vaccines. The industrial partner, Applikon, is aiming at developing disposable, single use bioreactors, which offer flexibility and require less investment in infrastructure compared to conventional bioreactors. Combining these strategies in this partnership will ultimately result in the development of vaccines in less time at lower costs.

This innovative project will lead to more fundamental knowledge on proteins and intracellular pathways important for viral replication by doing siRNA screens. This knowledge will be used to develop new Vero cell lines with modulated host genes using CRISPR-CAS9 that can significantly enhance virus production at reduced costs, thereby promoting global introduction of affordable vaccines. Also, we aim to use the knowledge obtained from the screens to design Vero cells that are capable of growing in suspension, which is a great advantage for easier scale-up and less expensive production of vaccines. The last aim is  to develop single-use, disposable bioreactors, that will eliminate the costs in the vaccine production process associated with disassembly, cleaning and reassembly of conventional bioreactors. This offers flexibility in vaccine development, and in change-over from one vaccine manufacturing process to another. In the last phase of this project, the modified Vero cells will be cultured at lab-scale in the disposable bioreactors developed by Applikon.